Results 271 to 280 of about 47,423 (289)
Some of the next articles are maybe not open access.
Chapter 5. Phosphodiesterase 4 inhibitors
2001Publisher Summary This chapter describes the various aspects of phosphodiesterase 4 (PDE4) inhibitors. PDE4 is the predominant isozyme present in inflammatory cells and selective PDE4 inhibitors are a popular target for novel anti-inflammatory drugs. The distribution of PDE4 in inflammatory cells and airway smooth muscle, and the effects of selective
John G. Montana, Hazel J. Dyke
openaire +1 more source
A chemometric study of phosphodiesterase 5 inhibitors
Journal of Molecular Graphics and Modelling, 2006This work presents a chemometric classification for a set of phosphodiesterase 5 inhibitors, based on a pattern recognition method widely used in quantitative structure-activity (QSAR) studies, hierarchical cluster analysis (HCA) and principal component analysis (PCA), aiming to access the most relevant structural and physicochemical variables related ...
Luciana Jansen, de O Figueiredo +4 more
openaire +2 more sources
Design of Second Generation Phosphodiesterase 5 Inhibitors
Current Topics in Medicinal Chemistry, 2007The clinical significance of phosphodiesterase 5 (PDE5) inhibition is increasingly understood following the pioneering work with sildenafil, and the continuing development programmes for both sildenafil and other marketed inhibitors. Since the initial launch of sildenafil for male erectile dysfunction (MED), approval has now been granted for treatment ...
Michael J, Palmer +3 more
openaire +2 more sources
Prescribing of Phosphodiesterase-5 Inhibitors Among Psychiatrists
Journal of Sex & Marital Therapy, 2013Phosphodiesterase-5 (PDE-5) inhibitors—avanafil, sildenafil, tadalafil, and vardenafil—are approved and widely used for treatment of erectile dysfunction of various etiologies.
Richard, Balon +2 more
openaire +2 more sources
Phosphodiesterase-5 inhibitors and their hemodynamic effects
Current Hypertension Reports, 2006Erectile dysfunction occurs commonly in untreated and treated hypertensive patients, impairing adherence to treatment and quality of life. Furthermore, it is a marker for enhanced risk for cardiovascular disease. Phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, provide effective treatment of erectile dysfunction.
openaire +2 more sources
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia
Current Opinion in Urology, 2010Benign prostatic hyperplasia (BPH) is prevalent in old men and often results in lower urinary tract symptoms (LUTS). Phosphodiesterase-5 (PDE5) inhibitors increase intracellular concentrations of cyclic guanosine monophosphate. PDE5 inhibitors (sildenafil, tadalafil, vardenafil, etc.) are first-line treatments for erectile dysfunction.
openaire +2 more sources
Phosphodiesterase 5 inhibitors in male sexual dysfunction
Current Opinion in Urology, 2003Phosphodiesterase 5 inhibitors are preferred by most men for the oral treatment of erectile dysfunction. In many guidelines, this therapy is recommended as first-line therapy because of convenience, high efficacy, and low rates of side-effects. Sildenafil was the first drug for the treatment of erectile dysfunction, introduced in 1998.
openaire +2 more sources
Phosphodiesterase‐5 Inhibitors and Migraine
Headache: The Journal of Head and Face Pain, 2004Evans, Randolph W +1 more
openaire +3 more sources
Phosphodiesterase 5 inhibitors in vascular systemic disorders
Joint Bone Spine, 2012Joint Bone Spine - In Press.Proof corrected by the author Available online since dimanche 11 mars ...
openaire +2 more sources
Pharmacology of phosphodiesterase 5 inhibitors.
The Canadian journal of urology, 2003The phosphodiesterase enzymes, of at least 11 types, are ubiquitous throughout the body, and perform a variety of functions. Phosphodiesterase type 5 (PDE5) is the predominant enzyme in the corpus cavernosum, and plays a crucial role in penile erection.
openaire +1 more source